Nikiforow, S., Whangbo, J. S., Reshef, R., Tsai, D. E., Bunin, N., Abu-Arja, R., Mahadeo, K. M., Weng, W.-K., Van Besien, K., Loeb, D., Nasta, S. D., Nemecek, E. R., Zhao, W., Sun, Y., Galderisi, F., Wahlstrom, J., Mehta, A., Gamelin, L., Dinavahi, R., & Prockop, S. (2024). Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Advances, 8(12), 3001–3012. https://doi.org/10.1182/bloodadvances.2023011626

Keller, M. D., Hanley, P. J., Chi, Y.-Y., Aguayo-Hiraldo, P., Dvorak, C. C., Verneris, M. R., Kohn, D. B., Pai, S.-Y., Dávila Saldaña, B. J., Hanisch, B., Quigg, T. C., Adams, R. H., Dahlberg, A., Chandrakasan, S., Hasan, H., Malvar, J., Jensen-Wachspress, M. A., Lazarski, C. A., Sani, G., … Pulsipher, M. A. (2024). Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-47057-2

Mahadeo, K. M., Baiocchi, R., Beitinjaneh, A., Chaganti, S., Choquet, S., Dierickx, D., Dinavahi, R., Duan, X., Gamelin, L., Ghobadi, A., Guzman-Becerra, N., Joshi, M., Mehta, A., Navarro, W. H., Nikiforow, S., O’Reilly, R. J., Reshef, R., Ruiz, F., Spindler, T., & Prockop, S. (2024). Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. The Lancet Oncology, 25(3), 376–387. https://doi.org/10.1016/s1470-2045(23)00649-6

Xu, M., Feng, R., Liu, Z., Zhou, X., Chen, Y., Cao, Y., Valeri, L., Li, Z., Liu, Z., Cao, S.-M., Liu, Q., Xie, S.-H., Chang, E. T., Jia, W.-H., Shen, J., Yao, Y., Cai, Y.-L., Zheng, Y., Zhang, Z., … Lin, X. (2024). Host genetic variants, Epstein-Barr virus subtypes, and the risk of nasopharyngeal carcinoma: Assessment of interaction and mediation. Cell Genomics, 4(2), 100474. https://doi.org/10.1016/j.xgen.2023.100474

Ford, M., Orlando, E., & Amengual, J. E. (2023). EBV Reactivation and Lymphomagenesis: More Questions than Answers. Current Hematologic Malignancy Reports, 18(6), 226–233. https://doi.org/10.1007/s11899-023-00708-5

Kinoshita, H., Mandava, M., Jensen-Wachspress, M., Lang, H., Joy, E., Tanna, J., McCann, C. D., O’Brien, S., Burnett, S., Shibli, A., Hoq, F., Bhatia, M., Hanley, P. J., Dávila Saldaña, B., Mahadeo, K. M., Bollard, C. M., Keller, M. D., & Abraham, A. (2023). Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease. Blood Advances, 7(10), 2105–2116. https://doi.org/10.1182/bloodadvances.2022008219

Afify, Z. A. M., Taj, M. M., Orjuela‐Grimm, M., Srivatsa, K., Miller, T. P., Edington, H. J., Dalal, M., Robles, J., Ford, J. B., Ehrhardt, M. J., Ureda, T. J., Rubinstein, J. D., McCormack, S., Rivers, J. M., Chisholm, K. M., Kavanaugh, M. K., Bukowinski, A. J., Friehling, E. D., Ford, M. C., … Mason, C. C. (2022). Multicenter study of pediatric Epstein‐Barr virus–negative monomorphic post solid organ transplant lymphoproliferative disorders. Cancer, 129(5), 780–789. Portico. https://doi.org/10.1002/cncr.34600

Patel, C., Pasciolla, M., Abramova, R., Salerno, D., Gomez-Arteaga, A., Shore, T. B., Orfali, N., Mayer, S., Hsu, J., Phillips, A. A., Chaekal, O.-K., Satlin, M. J., Soave, R., Kodiyanplakkal, R. P. L., Drelick, A., Plate, M., & Besien, K. V. (2023). Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients. Transplantation and Cellular Therapy, 29(2), 132.e1-132.e5. https://doi.org/10.1016/j.jtct.2022.10.023

Chen, J. K., Salerno, D. M., Corbo, H., Mantell, B. S., Richmond, M., Rothkopf, A., & Lytrivi, I. D. (2022). Immune cell function assay and T lymphocyte counts lack association with rejection or infection in pediatric heart transplant recipients. Clinical Transplantation, 37(2). Portico. https://doi.org/10.1111/ctr.14858

Zheng, B., Artin, M. G., Chung, H., Chen, B., Sun, S., May, B. L., Hur, C., Green, P. H. R., Wang, T. C., Park, J., & Kong, X. (2022). Immunogenetics of gastrointestinal cancers: A systematic review and retrospective survey of inborn errors of immunity in humans. Journal of Gastroenterology and Hepatology, 37(6), 973–982. Portico. https://doi.org/10.1111/jgh.15848

El-Atoum, B., Williams, M., Molina, K., Orjuela-Grimm, M. A., Prince, J., & Afify, Z. (2021). Burkitt Lymphoma After Cardiac Transplantation: Therapeutic Considerations. Journal of Pediatric Hematology/Oncology, 44(3), 100–102. https://doi.org/10.1097/mph.0000000000002260